



Dik Heg

Contact

Dik Heg

Publications (14)

Greutmann M, Tobler D, Engel R, Heg D, Mueller A, Frenk A, Gabriel H, Rutz T, Buechel R, Willhelm M, Trachsel L, Freese M, Ruperti-Repilado F, Valsangiacomo Buechel E, Beitzke D, Haaf P, Wustmann K, Schwitz F, Possner M, Schwitter J, Bouchardy J, Schwerzmann M, SERVE Investigators. Effect of phosphodiesterase-5 inhibition on SystEmic Right VEentricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE. *Eur J Heart Fail* 2023; 25:1105-1114.

Lenoir A, Christe A, Ebner L, Beigelman-Aubry C, Bridevaux P, Brutsche M, Clarenbach C, Erkosar B, Garzoni C, Geiser T, Guler S, Heg D, Lador F, Mancinetti M, Ott S, Piquilloud L, Prella M, Que Y, von Garnier C, Funke-Chambour M. Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study. *Respiration* 2022:1-14.

Iglesias J, Windecker S, Valgimigli M, Heg D, Kaiser C, Weilenmann D, Kurz D, Roffi M, Losdat S, Muller O, Pilgrim T. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. *Int J Cardiol* 2021; 334:37-41.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Brinkert M, Muller O, Tüller D, Degrauwe S, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. *Cardiovasc Revasc Med* 2021; 34:3-10.

Stoller M, Böhler A, Bloch N, Seiler C, Heg D, Branca M, Roten L. Effect of acute myocardial ischemia on inferolateral early repolarization. *Heart Rhythm* 2020; 17:922-930.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Rigamonti F, Lanz J, Tüller D, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. *J Am Heart Assoc* 2019; 8:e013607.

Iglesias J, Windecker S, Jüni P, Zwahlen M, Odutayo A, Valgimigli M, Eeckhout E, Losdat S, Stortecky S, Tapponnier M, Kaiser C, Weilenmann D, Moarof I, Kurz D, Roffi M, Heg D, Muller O, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. *Lancet* 2019; 394:1243-1253.

Iglesias J, Windecker S, Jüni P, Häner J, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Noble S, Tüller D, Roffi M, Heg D, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. *Circ Cardiovasc Interv* 2019; 12:e008024.

Pilgrim T, Jüni P, Eberli F, Hunziker L, Cuculi F, Kaiser C, Weilenmann D, Cook S, Siontis G, Moarof I, Muller O, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. *Lancet* 2018; 392:737-746.

Iglesias J, Windecker S, Jüni P, Eeckhout E, Valgimigli M, Heg D, Tapponnier M, Kaiser C, Weilenmann D, Vuilliamenet A, Kurz D, Roffi M, Zaugg S, Muller O, Pilgrim T. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. *EuroIntervention* 2018; 14:692-699.

Pilgrim T, Jüni P, Wenaweser P, Blöchliger S, Nietlispach F, Rigamonti F, Taniwaki M, Khattab A, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliamenet A, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. *EuroIntervention* 2015; 11

Franzone A, Jüni P, Wenaweser P, Stortecky S, Räber L, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliamenet A, Tüller D, Roffi M, Heg D, Pilgrim T, Windecker S. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. *Circ Cardiovasc Interv* 2015; 8

Pilgrim T, Jüni P, Wenaweser P, Eberli F, Noble S, Moschovitis A, Fahrni T, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliamenet A, Muller O, Tüller D, Roffi M, Heg D, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. *Lancet* 2014; 384:2111-22.

Pilgrim T, Jüni P, Heg D, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliamenet A, Muller O, Tüller D, Roffi M, Windecker S. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. *Am Heart J* 2014; 168:256-61.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch